COVID 19 TREATMENT

More in COVID 19 TREATMENT

• Molnupiravir authorisation comes with a condition - further trials in the next three months

  According to one of the conditions, as post marketing surveillance the companies will have to submit periodic safety update reports to the drug regulator.

  

• Russian drug Avifavir shows effectiveness in slowing COVID progression

  A meta analysis of 23 COVID-19 treatment studies for favipiravir demonstrated a 47% improvement when favipiravir is used in early treatment of coronavirus.

  

• Hetero to manufacture Anti-viral Covid-19 drug Movfor in India

  Hetero’s Movfor will be manufactured as a 40 capsule pack (200 mg per capsule) and will be marketed by its associate company ‘Hetero Healthcare’ across its distribution network in India.

  

• What is antibody therapy and who should take it - Expert answers

  The antibody therapy contains a mixture of two monoclonal antibodies that are Casirivimab and Imdevimab that act against SARS-CoV-2 virus causing COVID-19 spike protein.

  

• ICU blaze in Maharashtra kills 11; probe ordered

  The massive blaze engulfed the hospital in the morning, creating a huge panic among patients and staffers, as thick black smoke emanated from the ward.​

  

• Merck to seek emergency approval for experimental pill that cuts worst effects of coronavirus

  If cleared, Merck's drug - molnupiravir - would be the first pill shown to treat COVID-19, a potentially major advance in efforts to fight the pandemic. All COVID-19 therapies now authorized in the U.S. require an IV or injection.

  

• Hospitals have become large industries, thrive on human distress: SC

  "Hospitals have become a large industry now based on human distress. We cannot allow them to prosper at the cost of human lives. Let such hospitals be closed and allow the state to bolster health care facilities,” said Justice Chandrachud while noting that a number of hospitals don't adhere to fire safety norms.

  

• Laurus Labs receives licence from DRDO to manufacture and market COVID drug 2DG

  2DG has been given emergency approval by the Drugs Controller General of India (DCGI) for use on COVID-19 patients in the country, Laurus Labs said in a regulatory filing.

  

• Oxford University explores anti-parasitic drug ivermectin as Covid-19 treatment

  Ivermectin resulted in a reduction of virus replication in laboratory studies, the university said, adding that a small pilot showed giving the drug early could reduce viral load and the duration of symptoms in some patients with mild Covid-19.

  

• Indian pharma companies' sales to rise after resilience in FY21: Fitch

  Most pharma companies reported resilient operating performance in FY21, benefitting from gradual stabilisation after 1Q FY21, geographical diversification and sales of pandemic-related drugs.

  

• Healthcare company owner and pharma lab employee held in inter-state fake Favipiravir racket

  The drug has been widely used for Covid-19 treatment in the country. The case has sparked concern among activists on spurious drugs that have reached patients. The drugs are believed to have been sold in Maharashtra and Gujarat.